Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree. The SEC surely does not own shares of this junkaroo.
PROVECTUS & PFIZER ASSIGNED PATENT NUMBER 9808524
Combination of local and systemic immunomodulative therapies for melanoma and liver cancer
Well, you can't say nobody saw today's huge dump coming...
I have no idea what you think I said, but I said nothing about toothpicks. Nothing that has happened here is random.
As for your Chinese Bitcoin outfit... I see nothing suggesting anything about them is legit, but that doesn't matter one bitcoin, haha...
I'm not telling you or anyone else what to do. As I said, I was just explaining how the game works.
Feel free. As long as you know what you are doing, go for it.
I just periodically feel compelled to explain the game to newbies from time to time. Don't know why I do it, but I just get the itch to do so. I said all I needed to say.
As you were!
I don't think you understand how this works.
The share price can't get "real high". It is a pyramid scheme, essentially. All these stinky pinkies are. At some point, the pool of iHub investors (there aren't any other investors, except from other rube-filled pennystock forums) is exhausted. Everybody who wants in has gotten in. At that point, the price comes crashing down. Look at almost any stock on OTC and you will see triple-zero stocks shooting up for a day or two, wavering for a few days to a few weeks, and then crashing back to zero.
SANP's pool of buyers was drying up, the way it always goes. That's when it is time to dump. And dump he did, boy I tell ya... He's done it before, he knows the drill.
Matt, I'd like to commend you.
An earlier post of yours caught my eye, and it made me check out your posting history. You were a real believer. You even took off work one day after a restless night to watch the ticker, but it didn't turn out so well. I know it sucks to lose on something you believed in.
However, you did the right thing. Instead of listening to the constant drumbeat of fake news on the forum, you actually did some "due diligence". People use that word all the time around here, but almost nobody ever does it. They think reading PR's is doing due diligence.
So now, you've discovered the ugly truth. I think it might not have been easy to admit you were wrong, but you did. And you shared the info you found.
Next time, just try to control the excitement, and do the due diligence before you buy. 95% of the stocks on OTC are scams like this one, just with different names and different fake businesses. About 5% of the companies are real, and most of them will fail. That leaves a pool of about 20-25 companies a year worth taking a closer look at, and only 4 or 5 worth putting money in.
SANP had all the hallmarks from the start; a notorious CEO, a fishy history, weird Chinese involvement, purposely misleading PR's, no filings, nothing suggesting that anything was going on besides Frankie tweeting away, catching as many flies as he can... And if there were any doubt, the insane dilution today should have settled it.
You have the right impulses and now you learned a little something. You said your investment wasn't big, so just consider it tuition in the school of life. You'll do much better with the next one, I suspect.
As for SANP. Everyone should study it closely. It is a textbook pump-and-dump; you couldn't ask for a purer example. If anyone else besides Matt has a brain, I hope they learned a lesson here that will benefit them on future plays.
GLTA, but fuggedabout it on SANP
Nice! Highest close since June 13th.
Next week should be interesting... We may finally regain .05 if the company releases a PR on Tuesday to coincide with the awarding of those patents.
Impressed that this held over $170 after its off-hours surge; this strength reminds me of the good old days. Seems to be the real deal; robust support. The road to $200 is getting shorter...
How low will it go? This has to be bottoming out around here. Earning miss was by only 8/10 of a cent, and this has already taken the brunt of the soft gold market.
I wouldn't call it a "buy" yet, but it is a pretty good "average down" candidate.
Dude, when the bid/ask went to .0053/.0054 a few minutes ago, I won my bet.
You don't have to tell me "nice call", because it was an easy call. A baby could have told you.
But if you don't have the grace to admit you were wrong, then don't bother trying to spin it. You aren't worth the time I have wasted chatting with you already.
I am right about ICLD too. By the end of the day, or Monday at the latest, there won't even be a question about .0055
Watch and learn.
Seacrest out.
Oh please... You don't even have the grace to admit you were wrong. You said .0055 would hold, and I said it wouldn't. I was right, you were wrong.
Bragging about your "knowledge" of "the game" is giggle-inducing. lolol
There sure have been a lotta "games" the past 3 months, eh?
Boggles the mind how when the stock market is setting new all-time records, people still defend these diluting, insolvent, failing companies.
Ride the wave, my friend.
Oh, I guess you have delayed quotes.
So the dump I just watched breaching your .0055 is still in your future. lol
There went your .0055
lol, that was sure an easy call.
I follow lots of stocks. Good ones and crappy ones. I learn a lot that way; I don't need to buy the crappy ones to get some value from following them. You probably should follow more too.
Credit Suisse assumes coverage, rates SCI 'outperform' Price target =$40
https://www.benzinga.com/stock/sci/ratings
I wouldn't take them if you paid me to take them, Sugar. I make an effort not to buy garbage.
Scraps of worthless paper in a shell game? 'Cause that's what you own...
Much as I would like to think so, this has run $17/share in just a week. I think there will be a lot of sellers tomorrow. RSI was already at 70 yesterday, a signal to sell. It added $6 on earnings; it's top-heavy now.
Still a great hold, but I wouldn't buy it tomorrow.
lol, where are the whales today? At the beach?
It won't tomorrow.
It means absolutely nothing. Make note of anyone who tells you it has some meaning and keep their name on a list. Anybody who tells you a 911 trade means ANYTHING is a scam artist trying to steal your money. Or, an idiot noob. Either way, you never want to trust anything they say again.
Making a move over .04; I think we will enjoy this month.
$PVCT
Not sure what you posted, but it came up blank...
Provectus to be granted a new patent...
https://www.investorvillage.com/uploads/83031/files/20150290318.pdf
Dr. Wachter Declaration (from 2015 application):
https://www.investorvillage.com/uploads/83031/files/14974357.pdf
[PVCT holds 27 patents so far]
In other news, PV-10 trial recruiting has now begun at the new German site:
https://clinicaltrials.gov/ct2/show/NCT02288897?term=pv10&draw=2&rank=7
No PR's from PVCT about these (minor, but not insubstantial) developments, keeping in line with their vow to let the data speak for itself.
It is more proof that not only has business resumed at Provectus, they seem to be moving a lot faster than they have in the past.
$PVCT is gonna surprise people...
Nice earnings beat, as usual. This company has been so undervalued it is ridiculous. Oil is firming up, demand is rising, and this has an awful lot of headroom above.
I will be surprised if this is still around $10 in six months. RIG's best days still lie ahead.
There is no way it is good.
Face it guys, you've been set up.
"Greatness"??? Based on what? Linda mouthing off in her pathetic recital? Read the other one to see just how "great" this deadbeat company is.
Some quotes:
Digital Brand is a Florida corporation with no employees
Digital Brand is Unable to Get Current in its Periodic Reports
Digital Brand's violations are serious and egregious.
Digital Brand has made no efforts to cure its delinquencies,
and can make no credible assurance of future compliance
There are No Viable Excuses for Digital's Current Delinquencies.
Revocation is the Appropriate Remedy for Digital Brand.
https://www.sec.gov/litigation/apdocuments/3-17990-event-43.pdf
Greatness? lol
Apple is great. Amazon is great. Exxon, JP Morgan, Microsoft, Johnson & Johnson, Amgen... these are examples of "greatness"
Employee-less, penniless Linda, who is pretty much all of DBMM, not so much...
This board is filled with ridiculous disavowals of the reality of the situation here, and zero discussion of what is really going on. Fortunately, the principles of karma do indeed hold true even in the stock market. Maybe even especially true...
Wheeeee! 200 coming sooner than we think.
Nice earning beat today. Long-term, this should only keep going up...
lol Sure is relatively quiet on RSII board these days. Zero volume, eh? Gone are the days of 100 million shares traded... The circus has definitely left town.
This is going to slowly shrivel up and die.
Market doesn't like Moody's Baa1 rating for the new notes:
https://www.moodys.com/research/Moodys-rates-Verizons-new-notes-Baa1--PR_374426?WT.mc_id=AMRG93X0pvbmVzX05ld3NSb29tX1
Divvy yield is almost at 5% again; might be a good time to buy soon.
The whole board was replaced in May; we should be free of all the bad eggs now. The current board is vested and has financial motivation to finish the outstanding trials, sooner rather than later. There has been no official CEO named yet, but Dominic Rodrigues, Chairman of the Board, has been acting as a defacto CEO.
In last month's letter to shareholders, the first time we heard from PVCT management directly all year (8K's not withstanding), the company stated that rather than issue a lot of PR's, they would let the data speak for itself.
Since then, we've gotten two news releases both focused on data. This one is just a study of user experiences, but it is more data.
So, it seems the company wasn't kidding.
While this release isn't big enough to move the stock much by itself, it did manage to halt a sell-off that started on Thursday. So, I take it as a positive sign that the company is indeed back in business and people are indeed "watching" Good enough.
NEWS - PROVECTUS ANNOUNCES RESULTS FROM ELICITATION STUDY OF PATIENT-PERCEIVED IMPACTS FROM STAGE III AND EARLY-STAGE IV MELANOMA
– Key impacts comprised worry/concern, altered clothing choices, and limitations to physical functioning –
– Study results further support the clinical significance of Provectus’ ongoing, international, pivotal Phase 3 trial for locally advanced cutaneous melanoma (Stage IIIB-IVM1a) –
KNOXVILLE, TN, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (“Provectus” or the “Company”), a clinical-stage biotechnology company leading the development of the first small molecule oncolytic immunotherapy, intralesional (“IL”) PV-10, as a single agent for locally advanced disease as well as in combination with another agent for widely metastatic disease, both for multiple cancer indications, today announced that results from a Provectus-sponsored study to understand the daily life experiences of patients with locally advanced cutaneous melanoma were presented at the International Society for Quality of Life Research (“ISOQOL”) 24th Annual Conference in Philadelphia, Pennsylvania from October 18-21, 2017. Patient perceptions of their experiences related to this type of melanoma are not well understood.
Adults with Stage IIIB, IIIC, or IV M1a cutaneous melanoma at cancer centers in the U.S. and Australia were interviewed to elicit their day-to-day experiences with locally advanced cutaneous melanoma, and how this type of melanoma affected their everyday lives. These cancer sufferers described their most frequent symptoms as changes in skin appearance (from spreading to surrounding skin, the appearance of a bump or lump, the increase in number of lesions, and skin discoloration), and skin pain and discomfort (from bleeding, itchiness, sores, and painful sores). The impacts of their disease symptoms on daily life were reflected in nearly 500 distinct patient expressions. The highest impact categories conveyed by these melanoma patients were emotional health in general, sadness/depression, and physical functioning limited.
Provectus currently is undertaking an international, pivotal Phase 3 study of IL PV-10 versus chemotherapy (dacarbazine or temozolomide) or oncolytic viral therapy (IMLYGIC®, the first FDA-approved IL oncolytic virus therapy) in patients with locally advanced cutaneous melanoma (the same disease of the elicitation study) (NCT02288897). Stage IIIB, IIIC, or IV M1a melanoma patients with at least one injectable lesion who are not candidates for treatment with either a checkpoint inhibitor or targeted therapy with BRAF or combined BRAF/MEK inhibitors are eligible. The trial’s primary endpoint is progression free-survival (assessed via RECIST 1.1 every 12 weeks). Complete response rate (also assessed via RECIST 1.1) and overall survival are key secondary endpoints.
Dominic Rodrigues, Chairman of the Company’s Board of Directors, said, “These elicitation study data of patient-reported assessments of disease symptoms and quality of life show that patients afflicted with locally advanced cutaneous melanoma suffer important emotional impacts, presumably because they see their disease on a continuous basis.”
Mr. Rodrigues added, “Intralesional therapy in general, and intralesional PV-10 in particular, may shrink or eliminate these patients’ accessible and visible tumors. As a result, making these noticeable reminders of mortality diminish or disappear through treatment with intralesional therapy like PV-10 could be an important benefit for these melanoma cancer patients.”
A copy of the poster presentation is currently available on Provectus’ website at http://provectusbio.com/media/docs/publications/2017p-Patient-related-Impacts-Melanoma-(ISOQOL)-18Oct17.pdf.
About Provectus
Provectus is a clinical-stage biotechnology company leading the development of a new class of drugs based on halogenated xanthenes. Intralesional PV-10, the first small molecule oncolytic immunotherapy, is undergoing clinical study for adult solid tumor cancers like melanoma and cancers of the liver, and preclinical study for pediatric cancers. Topical PH-10 is undergoing clinical study for inflammatory dermatoses like psoriasis. Information about the Company’s clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company’s website at www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2016).
https://globenewswire.com/news-release/2017/10/23/1151502/0/en/PROVECTUS-ANNOUNCES-RESULTS-FROM-ELICITATION-STUDY-OF-PATIENT-PERCEIVED-IMPACTS-FROM-STAGE-III-AND-EARLY-STAGE-IV-MELANOMA.html
The psychological impulse is little more than "duh, what goes down must come up", which not only gets the physics of it backwards, but it fails to account for the thousands and thousands of companies littering ihub that went down and then stayed down, forever.
I don't get it myself. The stock market is setting record highs, and people pour their money into a dilutive, nearly bankrupt company that will soon be kicked off QB and land on the straight pinks. If it lasts that long.
No sense in trying to change anyone's minds. I just come for the trainwreck myself.
We are about to get creamed here. Last sale at .04 and now the spread is .0341/.0374?? Talk about the rug getting yanked out from under you, sheesh... Back to the old drawing board.
Your math is off...
The odds are 100% revocation, 0% no revocation.
So your odds are 100% unfavorable.
In an era when the stock market is setting new all-time highs almost every day, it boggles my mind that people cluster around a delisted, soon-to-be-revoked stock and pray for an unprecedented miracle. There are literally hundreds of stocks that have gone up substantially while people have been waiting for this dead dog to reanimate. Boggles the mind, I tells ya.
Gold can go to a million dollars an ounce and your shares will still be worthless. Do you not understand what revoked means?
That is why there is a Q at the end of the ticker. Anybody who buys a ticker with Q in it is knowingly buying a company in bankruptcy proceedings. You have no grounds for a lawsuit.